Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of NTR-1011 in Healthy Adults and Patients With SLE and RA
NCT07237659Phase 1Recruiting
- Sponsor
- Neutrolis, Inc.
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTR-1011 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (4 arms), sponsored by Neutrolis, Inc. Primary endpoint: Safety and tolerability at 30 days. Started Jul 2026; status: recruiting.
02
Drugs
NTR-1011
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07237659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237659.